Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function

European Journal of Heart Failure

Volumn 11, Issue 2, 2009, Pages 140-146

  Krenek, Peter ^a   Kmecova, Jana ^a   Kucerova, Dana ^a   Bajuszova, Zuzana ^a   Musil, Peter ^a   Gazova, Andrea ^b   Ochodnicky, Peter ^a   Klimas, Jan ^a   Kyselovic, Jan ^a  

^a Physics and Informatics   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

Heart rate; Isoproterenol induced heart failure; Nitric oxide; Nitric oxide synthases; Ventricular function

Indexed keywords

CAVEOLIN 1; CAVEOLIN 3; CELL CYCLE PROTEIN 37; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOPRENALINE; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CHRONOTROPISM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; ENZYME INHIBITION; HEART ATRIUM FUNCTION; HEART CATHETERIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART RATE; MALE; MUSCLE FIBER CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART ATRIUM; HEART CONTRACTION; HEART PACING; HEART VENTRICLE; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIAC PACING, ARTIFICIAL; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; HEART ATRIA; HEART FAILURE; HEART RATE; HEART VENTRICLES; ISOPROTERENOL; MALE; MYOCARDIAL CONTRACTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR;

EID: 64549149358     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn026     Document Type: Article

References (35)

1. Pelat M, Massion PB, Balligand JL Nitric oxide 'at heart': emerging paradigms after a decade. Arch Mal Coeur 2005;98:242-248.
2. Kojda G, Kottenberg K, Nix P, Schlüter KD, Piper HM, Noack E. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Grt Res 1996;78:91-101.
3. Stein B, Eschenhagen T, Rüdiger J, Scholz H, Förstermann U, Gath I. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. J Am Coll Cardiol 1998;32:1179-1186.
4. Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, Xu XB, Kobari Y, Pritchard K Jr, Sessa WC, Hintze TH. Reduced gene expression of vascular endo-thelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 1996;78: 58-64.
5. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Crosbie SM, Picard MH, Szelid Z, Gillijns H, Werf VF, Collen D, Bloch D. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocar-dial infarction. Circ Res 2004;94:1256-1262.
6. Ozaki M, Kawashima S, Yamashita T, Hirase T, Ohashi Y, Inoue N, Hirata K, Yokoyama M. Overexpression of endothelial nitric oxide synthase attenauates cardiac hypertrophy induced by chronic isoproterenol infusuon. Circ J 2002;66: 851 -856.
7. Prabhu SD. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 2004;94: 1256-1262.
8. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004;10:143-145.
9. Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, Shimokawa H, Takeshita A. Disruption of inducible nitric oxide synthase improves beta-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Cire Res 2002;90:959-965.
10. Thoenes M, Förstermann U, Tracey WR, Bleese NM, Nüssler AK, Scholz H, Stein B. Expression of inducible nitric oxide synthase in failing and non-failing human heart. J Mol Cell Cardiol 1996;28:165-169.
11. Heger J, Gödecke A, Flögel U, Merx MW, Molojavyi A, Kühn-Velten WN, Schrader J. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 2002;90:93-99.
12. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T, Schulz R, Butany J, Stewart DJ, Husain M. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002; 109:735-743.
13. BendallJK, Damy T, Ratajczak P, Loyer X, Monceau V, Marty I, Milliez P, Robidel E, Marotte F, Samuel JL, Heymes C. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 2004;110:2368-2375.
14. Damy T, Ratajczak P, Shah AM, Camors E, Marty I, Hasenfuss G, Marotte F, Samuel JL, Heymes C. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004;363:1365-1367.
15. SzaboJ, Csaky L, SzegiJ. Experimental cardiac hypertrophy induced by isoproterenol in the rat. Acta Physiol Acad Sci Hung 1975;46:281- 285.
16. Krenek P, Klimas J, Kroslakova M, Gazova A, Plandorova J, Kucerova D, Fecenkova A, Svec P, Kyselovic J. Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy. CanJ Physiol Pharmacol 2006;84:1245-1250.
17. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 2006;69:788-797.
18. Bacharova L, Kyselovic J, Klimas J. The initial stage of left ventricular hypertrophy in spontaneously hypertensive rats is manifested by a decrease in the QRS amplitude/left ventricular mass ratio. Clin Exp Hypertens 2004;26:557-567.
19. Hart CYT, Burnett JC, Redfield M. Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol 2001;H1938-H1945.
20. Kirchhefer U, Klimas J, Baba HA, Buchwalow IB, Fabritz L, Huls M, Matus M, Muller FU, Schmitz W, Neumann J. Triadin is a critical determinant of cellular Ca cycling and contractility in the heart. Am J Physiol Heart Circ Physiol 2007; 293:H3165-H3174.
21. Danson EJ, Zhang YH, Sears CE, Edwards AR, Casadei B, Paterson DJ. Disruption of inhibitory G-proteins mediates a reduction in atrial beta-adrenergic signaling by enhancing eNOS expression. Cardiovasc Res 2005;67:575-577.
22. Brunner F, Andrew P, Wölkart G, Zechner R, Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001;104:3097- 3102.
23. Sterin-Borda L, Bernabeo G, Ganzinelli S, Joensen L, Borda E. Role of nitric oxide/ cyclic GMP and cyclic AMP in beta3 adrenoceptor-chronotropic response. J Mol Cell Cardiol 2006;40:580-588.
24. Setty S, Tune JD, Downey HF. Nitric oxide modulates right ventricular flow and oxygen consumption during norepinephrine infusion. Am J Physiol Heart Circ Physiol 2002;282:H696-H703.
25. Smith RS Jr, Agata J, Xia CF, Chao L, Chao J. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 2005;76:2457-2471.
26. Linck B, Boknik P, Baba HA, Eschenhagen T, Haverkamp U, Jackel E, Jones LR, Kirchhefer U, Knapp J, Laer S, Muller FU, Schmitz W, Scholz H, Syska A, Vahlensieck U, Neumann J. Long-term beta adrenoceptor-mediated alteration in contractility and expression of phospholamban and sarcoplasmic reticulum Ca(pp)-ATPase in mammalian ventricle. J Pharmacol Exp Ther 1998;286: 531-538.
27. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacher PR, Bishopric NH, Cooke JP, McKenna WJ, Fowler MB. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-1094.
28. Grosjean SA, Arstall MA, Mitchell RN, Klappacher GW, Kelly RA, Pfeffer MA, Pfeffer JM. Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injection. J Card Fail 1999;5:236-245.
29. Hu A, Jiao X, Gao E, Koch WJ, Sharifi-Azad S, Grunwald Z, Ma XL, Sun JZ. Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress. J Pharmacol Exp Ther 2006;318:469-475.
30. Shizukuda Y, Buttrick PM, Geenen DL, Borczuk AC, Kitsis RN, Sonnenblick EH. Beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol 1998;275:H961-H968.
31. Piech A, Dessy C, Havaux X, Feron O, Balligand JL. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res 2003;57:456-467.
32. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L, Nagai Y, Fujisawa Y, Miyatake A, Abe Y. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 2005;65:230-238.
33. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after and continuing. Circ Res 2003;93:388- 398.
34. Yamamoto S, Tsutsui H, Tagawa H, Saito K, Takahashi M, Tada H, Yamamoto M, Katoh M, Egashira K, Takeshita A. Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Circulation 1997;95:1111-1114.
35. Kotchi KE, Weisselberg T, Röhnert P, Preiss M, Heinroth-Hoffmann I, Osten B, Brodde OE. Nitric oxide inhibits isoprenaline-induced positive inotropic effects in normal, but not in hypertrophied rat heart. Naunyn Schmiedebergs Arch Pharmacol 1998;357:579-583.